News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ceragenix Pharmaceuticals, Inc. (CGXP.OB) Achieves 200 Days of Antimicrobial Efficacy on Treated Silicone Medical Device



5/4/2009 9:12:31 AM

DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) (the "Company"), a medical device company focused on infectious disease and dermatology, today announced that preclinical testing of a silicone medical device incorporating the Company’s CeraShield™ antimicrobial technology has achieved 200 days of continuous antimicrobial efficacy. The prototype device being tested is an intravaginal silicone ring. Antimicrobial intravaginal rings may be of potential benefit in preventing transmission of certain sexually transmitted diseases. The Company had previously announced when it had achieved 120 days of continuous efficacy in the same study.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES